Ann M. Arvin

Publication Details

  • IMMUNITY IN STRAIN-2 GUINEA-PIGS INOCULATED WITH VACCINIA VIRUS RECOMBINANTS EXPRESSING VARICELLA-ZOSTER VIRUS GLYCOPROTEINS-I, GLYCOPROTEIN-IV, GLYCOPROTEIN-V OR THE PROTEIN PRODUCT OF THE IMMEDIATE EARLY GENE-62 JOURNAL OF GENERAL VIROLOGY Lowry, P. W., SOLEM, S., Watson, B. N., Koropchak, C. M., THACKRAY, H. M., Kinchington, P. R., Ruyechan, W. T., Ling, P., Hay, J., Arvin, A. M. 1992; 73: 811-819

    Abstract:

    The immunogenicity of specific varicella-zoster virus (VZV) proteins, with emphasis upon cell-mediated immune responses, was evaluated by immunizing strain 2 guinea-pigs with vaccinia virus recombinants that express gpI (vac-gpI), gpIV (vac-gpIV) and gpV (vac-gpV) or the IE-62 protein (vac-IE-62). Vac-gpI elicited the highest initial mean T cell proliferation response [stimulation index (S.I.) 3.8 +/- 0.9 S.E.M.] whereas inoculation with vac-gpV produced the lowest primary T cell response (S.I. 2.5 +/- 1.1 S.E.M.). T cell proliferation was detected for a shorter period after immunization with vac-gpV compared to vac-gpI, vac-gpIV or vac-IE-62. A comparison of the immunogenicity of vac-gpI and vac-IE-62 with the same proteins prepared by immunoaffinity purification showed that immunization with these proteins in either form elicited virus-specific IgG antibodies and T cell recognition. The presence or absence of IgG antibodies to the IE-62 protein was used to assess protection against challenge with guinea-pig cell-adapted infectious VZV in animals that had been inoculated with vac-gpI, vac-gpIV or vac-gpV. Immunization with vac-gpI and vac-gpIV restricted VZV replication but all animals given vac-gpV developed antibodies to IE-62 after challenge with infectious VZV. Priming of the T lymphocyte response was observed in all animals immunized with VZV-vaccinia virus recombinants after subsequent exposure to infectious VZV. These experiments with VZV vac-gpI, vac-gpIV and vac-gpV in guinea-pigs suggest variability in the capacity of herpesviral glycoproteins to elicit cell-mediated immunity in vivo. Induction of virus-specific immunity using IE-62 means that this major tegument protein of VZV could be a useful component for vaccine development.

    View details for Web of Science ID A1992HM86100008

    View details for PubMedID 1321876

Stanford Medicine Resources:

Footer Links: